1. Home
  2. GKOS vs THG Comparison

GKOS vs THG Comparison

Compare GKOS & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • THG
  • Stock Information
  • Founded
  • GKOS 1998
  • THG 1852
  • Country
  • GKOS United States
  • THG United States
  • Employees
  • GKOS N/A
  • THG N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • THG Property-Casualty Insurers
  • Sector
  • GKOS Health Care
  • THG Finance
  • Exchange
  • GKOS Nasdaq
  • THG Nasdaq
  • Market Cap
  • GKOS 5.8B
  • THG 6.0B
  • IPO Year
  • GKOS 2015
  • THG 1995
  • Fundamental
  • Price
  • GKOS $89.83
  • THG $169.60
  • Analyst Decision
  • GKOS Strong Buy
  • THG Buy
  • Analyst Count
  • GKOS 12
  • THG 9
  • Target Price
  • GKOS $131.17
  • THG $183.44
  • AVG Volume (30 Days)
  • GKOS 1.2M
  • THG 258.1K
  • Earning Date
  • GKOS 07-30-2025
  • THG 07-30-2025
  • Dividend Yield
  • GKOS N/A
  • THG 2.12%
  • EPS Growth
  • GKOS N/A
  • THG 102.68
  • EPS
  • GKOS N/A
  • THG 15.19
  • Revenue
  • GKOS $432,953,000.00
  • THG $6,407,200,000.00
  • Revenue This Year
  • GKOS $27.88
  • THG $4.98
  • Revenue Next Year
  • GKOS $27.76
  • THG $6.17
  • P/E Ratio
  • GKOS N/A
  • THG $11.16
  • Revenue Growth
  • GKOS 26.70
  • THG 4.47
  • 52 Week Low
  • GKOS $77.10
  • THG $132.93
  • 52 Week High
  • GKOS $163.71
  • THG $178.68
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 43.89
  • THG 51.86
  • Support Level
  • GKOS $88.94
  • THG $168.65
  • Resistance Level
  • GKOS $92.70
  • THG $173.57
  • Average True Range (ATR)
  • GKOS 3.82
  • THG 3.55
  • MACD
  • GKOS 0.38
  • THG 0.18
  • Stochastic Oscillator
  • GKOS 46.71
  • THG 35.27

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About THG Hanover Insurance Group Inc

The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.

Share on Social Networks: